UK-based George Health reported on Monday the receipt of GBP27m in new financing to fast-track new treatments for chronic diseases such as cardiovascular and Type 2 diabetes, said to be the world's biggest killers.
This funding round was led by Bupa Australia, Federation Asset Management and the Australian Government-backed Medical Research Commercialisation Fund Biomedical Translation Fund (MRCF BTF), managed by Brandon Capital Partners.
Under the agreement, George Health will receive GBP17m from Federation Asset Management and Bupa Australia to accelerate the development of drugs for multiple chronic diseases as well as an ultra-low-cost dialysis system for patients with end-stage kidney failure.
Additionally, George Medicines will receive just over GBP10m from the Australian Government-backed Medical Research Commercialisation Fund Biomedical Translation Fund (MRCF BTF), matched by George Health Enterprises, which will see a GBP20m financial boost to bring to market a near-registration medicine for treating recurrent heart attacks, high blood pressure .
Formed in 2014, George Health Enterprises is the commercial arm of The George Institute for Global Health. George Health (GH) is a for-profit fully-integrated global health care company committed to providing high-quality, affordable health products and services at scale.
(USD1=GBP0.765308)
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults